

Ironwood Pharmaceuticals Inc (IRWD) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/I4B8A0D1450EN.html>

Date: April 2021

Pages: 64

Price: US\$ 125.00 (Single User License)

ID: I4B8A0D1450EN

Abstracts

Ironwood Pharmaceuticals Inc (IRWD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ironwood Pharmaceuticals Inc (Ironwood) discovers, develops and commercializes drugs for gastrointestinal disorders. Its marketed product include Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) in adults. Ironwood also evaluates linaclotide in other indications, new formulations and in combination with other products in various GI conditions including IBS-C or FC in pediatrics. It is also advancing IW-3300, a guanylate cyclase-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/ bladder pain syndrome and endometriosis. Ironwood is headquartered in Cambridge, Massachusetts, the US.

Ironwood Pharmaceuticals Inc Key Recent Developments

Mar 30,2021: Ironwood Pharmaceuticals announces management changes

Feb 17,2021: Ironwood Pharmaceuticals reports fourth quarter and full year 2020 results exceeding or meeting full year 2020 financial guidance provides full year 2021 financial guidance

Feb 08,2021: Ironwood Pharmaceuticals announces CEO transition

Dec 03,2020: Ironwood Pharmaceuticals appoints Jay P. Shepard to Board of Directors

Nov 05,2020: Ironwood Pharmaceuticals reports strong third quarter 2020 results and increases full year 2020 financial guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Ironwood Pharmaceuticals Inc - Key Facts
Ironwood Pharmaceuticals Inc - Key Employees
Ironwood Pharmaceuticals Inc - Key Employee Biographies
Ironwood Pharmaceuticals Inc - Major Products and Services
Ironwood Pharmaceuticals Inc - History
Ironwood Pharmaceuticals Inc - Company Statement
Ironwood Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Ironwood Pharmaceuticals Inc - Business Description
Other Break-up: Collaborative Arrangements Revenue
Performance
Other Break-up: Product Revenue
Performance
Other Break-up: Sale of Active Pharmaceutical Ingredient
Performance
Ironwood Pharmaceuticals Inc - Corporate Strategy
Ironwood Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Ironwood Pharmaceuticals Inc - Strengths
Ironwood Pharmaceuticals Inc - Weaknesses
Ironwood Pharmaceuticals Inc - Opportunities
Ironwood Pharmaceuticals Inc - Threats
Ironwood Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Ironwood Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 30, 2021: Ironwood Pharmaceuticals announces management changes

Feb 17, 2021: Ironwood Pharmaceuticals reports fourth quarter and full year 2020 results exceeding or meeting full year 2020 financial guidance provides full year 2021 financial guidance

Feb 08, 2021: Ironwood Pharmaceuticals announces CEO transition

Dec 03, 2020: Ironwood Pharmaceuticals appoints Jay P. Shepard to Board of Directors

Nov 05, 2020: Ironwood Pharmaceuticals appoints Alexander Denner, Ph.D., to Board of Directors

Nov 05, 2020: Ironwood Pharmaceuticals reports strong third quarter 2020 results and increases full year 2020 financial guidance

Sep 29, 2020: Ironwood to cut 100 jobs after digestive disease drug fails study

Aug 06, 2020: Ironwood Pharmaceuticals reports second quarter 2020 results; delivered GAAP net income of \$25 million and adjusted EBITDA of \$33 million

Mar 26, 2020: Ironwood Pharmaceuticals provides update on impact of COVID-19

Feb 13, 2020: Ironwood Pharmaceuticals reports strong fourth quarter and full year 2019 results, exceeding full year 2019 guidance; provides full year 2020 guidance

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Ironwood Pharmaceuticals Inc, Key Facts
Ironwood Pharmaceuticals Inc, Key Employees
Ironwood Pharmaceuticals Inc, Key Employee Biographies
Ironwood Pharmaceuticals Inc, Major Products and Services
Ironwood Pharmaceuticals Inc, History
Ironwood Pharmaceuticals Inc, Subsidiaries
Ironwood Pharmaceuticals Inc, Key Competitors
Ironwood Pharmaceuticals Inc, Ratios based on current share price
Ironwood Pharmaceuticals Inc, Annual Ratios
Ironwood Pharmaceuticals Inc, Annual Ratios (Cont...1)
Ironwood Pharmaceuticals Inc, Annual Ratios (Cont...2)
Ironwood Pharmaceuticals Inc, Interim Ratios
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ironwood Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Ironwood Pharmaceuticals Inc, Performance Chart (2016 - 2020)

Ironwood Pharmaceuticals Inc, Ratio Charts

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Ironwood Pharmaceuticals Inc (IRWD) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/l4B8A0D1450EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l4B8A0D1450EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970